NGM Biopharmaceuticals Gets FDA Fast Track Designation for Vision Treatment

 NGM Biopharmaceuticals Inc. said the U.S. Food and Drug Administration has granted Fast Track designation to NGM621 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.

The biotechnology company said it is evaluating NGM621 in an ongoing Phase 2 study and a topline data readout is expected in the fourth quarter.

The Fast Track process was designed by the FDA to help the development and expedite the review of potential therapeutics intended to treat serious conditions and address unmet medical needs.

https://www.marketscreener.com/quote/stock/NGM-BIOPHARMACEUTICALS-I-56727727/news/NGM-Biopharmaceuticals-Gets-FDA-Fast-Track-Designation-for-Vision-Treatment-37803404/